Skip Navigation
Search Menu
Find an Expert


Stephen B. Baylin, M.D.

Photo of Dr. Stephen B. Baylin, M.D.

Virginia and D.K. Ludwig Professor for Cancer Research Professor of Oncology and Medicine

Professor of Oncology

Research Interests: Epigenetics


Stephen B. Baylin, M.D., is Virginia and D.K. Ludwig Professor of Oncology and Medicine, Co-Director of the Cancer Biology Division and Associate Director for Research Programs of The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. 

Dr. Baylin attended Duke University, where he earned his medical degree in 1968 and completed his internship and first year residency in internal medicine. He then worked for two years at the National Heart and Lung Institute of the National Institutes of Health (NIH). In 1971, Dr. Baylin joined the departments of oncology and medicine at Johns Hopkins University School of Medicine.

His research interests include cellular biology and genetics of cancer, specifically epigenetics or genetic modifications other than those in DNA that can affect cell behavior, and silencing of tumor suppressor genes and tumor progression. His research has looked at the mechanisms through which variations in tumor cells derive, and cell differentiation in cancers such as medullary thyroid carcinoma and small cell lung carcinoma.

Dr. Baylin’s honors include the 2004 National Investigator of the Year Award from the NCI SPORE program; the 2005 Jack Gibson Visiting Professorship, University of Hong Kong Queen Mary Hospital, Hong Kong; the 2005 Shubitz Cancer Research Prize from the University of Chicago; the 2008 Raffaele Tecce Memorial Lecture, Rome, Italy; the 2008 David Workman Memorial Award from the Waxman Foundation; the 2009 Kirk A. Landon-AACR Prize for Basic and Translational Cancer Research (jointly with Peter A. Jones, Ph.D.); the 2010 14th NCI Alfred G. Knudson Award in Cancer Genetics and the 2011 American Cancer  Society’s Medal of Honor Award (jointly with Peter A. Jones, Ph.D.) and most recently the Fellows of The American Association of Cancer Research  – Academy Class of 2014. 

Dr. Baylin has served on the American Association for Cancer Research Board of Directors from 2004 through 2007, and is an associate editor of Cancer Research. He has also presented frequently at AACR conferences and chaired the special conference on “DNA Methylation, Imprinting and the Epigenetics of Cancer.” Dr. Baylin has authored or co-authored more than 400 publications. more


  • Virginia and D.K. Ludwig Professor for Cancer Research Professor of Oncology and Medicine
  • Co-director, Cancer Biology Research Program, Sidney Kimmel Cancer Center
  • Professor of Oncology
  • Professor of Medicine

Centers & Institutes

Research & Publications

Research Summary

Our research has contributed heavily to the concept that epigenetically mediated loss of gene function is a major player in the progression of human cancer. This process, for which aberrant gene promoter hypermethylation is a signature and a component of aberrant loss of transcription for involved genes, is now known to be an alternative to coding region mutations for loss of function of more than half the classic tumor suppressor genes and for a growing list of candidate tumor suppressor genes in virtually every type of human cancer. We are attempting to understand the abnormalities of chromatin and methylation assembly that may account for the appearance of these epigenetic abnormalities during tumor development and how they mediate the transcriptional repression. We are learning, in this regard, that an interaction between the DNA methylation, histone de-acetylase (HDAC) and histone methylating enzymes mediates the transcriptional silencing. We have also discovered that the enzymes that catalyze DNA methylation, the DNA methyltransferases (DNMTs), are more complex than previously thought and can both inhibit transcription and interact with HDACs, independent of mediating the methylation. In collaboration with the Vogelstein-Kinzler lab, we have identified that an interaction between DNMTs is required in colon cancer cells to maintain the abnormal promoter methylation and silencing of important tumor suppressor genes. All of these studies are giving us a much more complete picture of the machinery that mediates aberrant promoter methylation in cancer. They also are contributing to the translational goal of targeting reversal of abnormal gene silencing as a cancer prevention and/or therapy strategy.

Core Facility: SKCCC Experimental and Computational Genomics Core

Selected Publications

View all on Pubmed

  1. Zhang, W.; Zeng, X.; Briggs, K.J.; Beaty, R.; Simons, B.; Chiu Yen, R.W.; Tyler, M.A.; Tsai, H.C.; Ye, Y.; Gesell, G.S.; Herman, J.G.; Baylin, S.B.; Watkins, D.N. A potential tumor suppressor role for Hic1 in breast cancer through transcriptional repression of ephrin-A1. Oncogene. 2010 Apr 29;29(17):2467-2476
  2. Zahnow, C.A.; Baylin, S.B. Epigenetic networks and miRNAs in stem cells and cancer. Mol Cell. 2010 Sep 10;39(5):661-663.
  3. Tiwari, V.K.; Baylin, S.B. Mapping networks of protein-mediated physical interactions between chromatin elements. Curr Protoc Mol Biol. 2010 Jan;Chapter 21:Unit 21 16 21-13.
  4. Ohm, J.E.; Mali, P.; Van Neste, L.; Berman, D.M.; Liang, L.; Pandiyan, K.; Briggs, K.J.; Zhang, W.; Argani, P.; Simons, B.; Yu, W.; Matsui, W.; Van Criekinge, W.; Rassool, F.V.; Zambidis, E.; Schuebel, K.E.; Cope, L.; Yen, J.; Mohammad, H.P.; Cheng, L.; Baylin, S.B. Cancer-related epigenome changes associated with reprogramming to induced pluripotent stem cells. Cancer Res. 2010 Oct 1;70(19):7662-7673.
  5. Noushmehr, H.; Weisenberger, D.J.; Diefes, K.; Phillips, H.S.; Pujara, K.; Berman, B.P.; Pan, F.; Pelloski, C.E.; Sulman, E.P.; Bhat, K.P.; Verhaak, R.G.; Hoadley, K.A.; Hayes, D.N.; Perou, C.M.; Schmidt, H.K.; Ding, L.; Wilson, R.K.; Van Den Berg, D.; Shen, H.; Bengtsson, H.; Neuvial, P.; Cope, L.M.; Buckley, J.; Herman, J.G.; Baylin, S.B.; Laird, P.W.; Aldape, K. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010 May 18;17(5):510-522.
  6. Mohammad, H.P.; Baylin, S.B. Linking cell signaling and the epigenetic machinery. Nat Biotechnol. 2010 Oct;28(10):1033-1038.
  7. Mali, P.; Chou, B.K.; Yen, J.; Ye, Z.; Zou, J.; Dowey, S.; Brodsky, R.A.; Ohm, J.E.; Yu, W.; Baylin, S.B.; Yusa, K.; Bradley, A.; Meyers, D.J.; Mukherjee, C.; Cole, P.A.; Cheng, L. Butyrate greatly enhances derivation of human induced pluripotent stem cells by promoting epigenetic remodeling and the expression of pluripotency-associated genes. Stem Cells. 2010 Apr;28(4):713-720.
  8. Licchesi, J.D.; Van Neste, L.; Tiwari, V.K.; Cope, L.; Lin, X.; Baylin, S.B.; Herman, J.G. Transcriptional regulation of Wnt inhibitory factor-1 by Miz-1/c-Myc. Oncogene. 2010 Nov 4;29(44):5923-5934.
  9. Johnstone, S.E.; Baylin, S.B. Stress and the epigenetic landscape: a link to the pathobiology of human diseases? Nat Rev Genet. 2010 Nov;11(11):806-812.
  10. Easwaran, H.P.; Van Neste, L.; Cope, L.; Sen, S.; Mohammad, H.P.; Pageau, G.J.; Lawrence, J.B.; Herman, J.G.; Schuebel, K.E.; Baylin, S.B. Aberrant silencing of cancer-related genes by CpG hypermethylation occurs independently of their spatial organization in the nucleus. Cancer Res. 2010 Oct 15;70(20):8015-8024 NIHMSID # 263537 PMCID Journal: In process.

Activities & Honors


  • Simon M. Shubitz Cancer Prize and Lectureship, 2005
Is this you? Edit Profile